Literature DB >> 19158154

Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor.

Jia-Jun Liao1, Mei-Chuan Huang, Katharine Fast, Katherine Gundling, Mahesh Yadav, James R Van Brocklyn, Matthias R Wabl, Edward J Goetzl.   

Abstract

Anti-lymphocyte antibodies (Abs) that suppress T-cell chemotactic and other responses to sphingosine 1-phosphate (S1P), but not to chemokines, were found in a lymphopenic patient with recurrent infections. Lymphocyte type 1 S1P receptor (S1P(1)) that transduces S1P chemotactic stimulation was recognized by patient Abs in Western blots of T cells, S1P(1) transfectants, and S1P(1)-hemagglutinin purified by monoclonal anti-hemagglutinin Ab absorption. The amino terminus of S1P(1), but not any extracellular loop, prevented anti-S1P(1) Ab suppression of S1P(1) signaling and T-cell chemotaxis to S1P. Human purified anti-S1P(1) Abs decreased mouse blood lymphocyte levels by a mean of 72%, suppressed mouse T-cell chemotaxis to S1P in vivo, and significantly reduced the severity of dextran sodium sulfate-induced colitis in mice. Human Abs to the amino terminus of S1P(1) suppress T-cell trafficking sufficiently to impair host defense and provide therapeutic immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158154      PMCID: PMC2698662          DOI: 10.1096/fj.08-124891

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  36 in total

1.  The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.

Authors:  Markus H Gräler; Edward J Goetzl
Journal:  FASEB J       Date:  2004-01-08       Impact factor: 5.191

2.  Identification of three major target molecules of IgM antilymphocyte autoantibodies in systemic lupus erythematosus.

Authors:  S Minota; J B Winfield
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

3.  Autoantibodies against ganglioside GM3 represent a portion of anti-lymphocyte antibodies in AIDS patients.

Authors:  T Griggi; R Bauer; T Garofalo; S Kukel; L Lenti; A P Massetti; C Müller; M Sorice; G M Pontieri
Journal:  Scand J Immunol       Date:  1994-07       Impact factor: 3.487

4.  Nature of autolymphocytotoxins present in renal hemodialysis patients. Their possible role in controlling alloantibody formation.

Authors:  P I Lobo
Journal:  Transplantation       Date:  1981-09       Impact factor: 4.939

5.  Specificity of anti-lymphocyte antibodies in sera from patients with AIDS-related complex (ARC) and healthy homosexuals.

Authors:  R Q Warren; E A Johnson; R P Donnelly; M F Lavia; K Y Tsang
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

6.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.

Authors:  Mehrdad Matloubian; Charles G Lo; Guy Cinamon; Matthew J Lesneski; Ying Xu; Volker Brinkmann; Maria L Allende; Richard L Proia; Jason G Cyster
Journal:  Nature       Date:  2004-01-22       Impact factor: 49.962

7.  An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells.

Authors:  R B Stricker; T M McHugh; D J Moody; W J Morrow; D P Stites; M A Shuman; J A Levy
Journal:  Nature       Date:  1987 Jun 25-Jul 1       Impact factor: 49.962

8.  Characterization of cold reactive lymphocytotoxic antibodies in malaria.

Authors:  M J Gilbreath; K Pavanand; R P MacDermott; R A Wells; M A Ussery
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

9.  Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus.

Authors:  T Mimura; P Fernsten; W Jarjour; J B Winfield
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

10.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

Authors:  Elisabetta Traggiai; Stephan Becker; Kanta Subbarao; Larissa Kolesnikova; Yasushi Uematsu; Maria Rita Gismondo; Brian R Murphy; Rino Rappuoli; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  8 in total

1.  Defective T cell chemotaxis to sphingosine 1-phosphate and chemokine CCL21 in idiopathic T lymphocytopenia.

Authors:  Edward J Goetzl; Janice B Schwartz; Mei-Chuan Huang
Journal:  J Clin Immunol       Date:  2011-06-14       Impact factor: 8.317

2.  Unique ligand-binding property of the human IgM Fc receptor.

Authors:  Kazuhito Honjo; Yoshiki Kubagawa; John F Kearney; Hiromi Kubagawa
Journal:  J Immunol       Date:  2015-01-19       Impact factor: 5.422

3.  Soluble Fc Receptor for IgM in Sera From Subsets of Patients With Chronic Lymphocytic Leukemia as Determined by a New Mouse Monoclonal Antibody.

Authors:  Pedram Mahmoudi Aliabadi; Ruth Teuber; Peter K Jani; Landon Wilson; Philipp Enghard; Stephen Barnes; Nicholas Chiorazzi; Andreas Radbruch; Fritz Melchers; Hiromi Kubagawa
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

4.  Autoimmunity to Sphingosine-1-Phosphate-Receptors in Systemic Sclerosis and Pulmonary Arterial Hypertension.

Authors:  Hans Gluschke; Elise Siegert; Waldemar B Minich; Julian Hackler; Gabriela Riemekasten; Wolfgang M Kuebler; Szandor Simmons; Lutz Schomburg
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

5.  T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy.

Authors:  Cristiano Alessandri; Cristiana Barbati; Davide Vacirca; Paola Piscopo; Annamaria Confaloni; Massimo Sanchez; Angela Maselli; Tania Colasanti; Fabrizio Conti; Simona Truglia; Andras Perl; Guido Valesini; Walter Malorni; Elena Ortona; Marina Pierdominici
Journal:  FASEB J       Date:  2012-07-26       Impact factor: 5.191

Review 6.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

7.  Capturing the finer points of gene expression in psoriasis: beaming in on the CCL19/CCR7 axis.

Authors:  Laure Rittié; James T Elder
Journal:  J Invest Dermatol       Date:  2012-06       Impact factor: 8.551

8.  Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease.

Authors:  T Karuppuchamy; E-H Behrens; P González-Cabrera; G Sarkisyan; L Gima; J D Boyer; G Bamias; P Jedlicka; M Veny; D Clark; R Peach; F Scott; H Rosen; J Rivera-Nieves
Journal:  Mucosal Immunol       Date:  2016-04-06       Impact factor: 7.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.